BY: SAMANTHA BARTLETT, DVM

A new treatment to control arthritis pain in cats has been approved by the FDA for Zoetis. Solensia (frunevetmab) is a monoclonal antibody and is the first such approved drug for any animal species. Since treatment options for cats with osteoarthritis, this new addition the veterinary arsenal is much anticipated.

The feline specific monoclonal antibody attaches to nerve growth factor protein involved in the regulation of pain. When the antibody binds with the protein it blocks the pain signal from reaching the brain. The drug is a once monthly subcutaneous injection based on the animal’s body weight. 

Effectiveness was tested in two masked, randomized clinical trials with client-owned cats. Veterinarians assessed the cats with orthopedic exams before and after treatment. Owners were also asked to score their cat’s abilities doing specific activities such as jumping on furniture, using the litterbox and groom. They were asked to compare those scores to the same activities after treatment. Researchers found an overall better assessment after treatment than cats in the control group. Side effects included diarrhea, vomiting, injection site pain, and dermatitis. 

Zoetis anticipates Solensia will be available to veterinary clinics later this year (2022).